辉瑞新冠疫苗三期大规模试验显示轻度至中度副作用

2020-09-16 JACK ZHAO MedSci原创

副作用包括疲劳,头痛,发冷和肌肉疼痛

副作用包括疲劳,头痛,发冷和肌肉疼痛

 

辉瑞公司(Pfizer Inc.)高管在周二一次投资者电话会议上表示,在正在进行的后期研究中,使用该公司的试验性新冠疫苗或安慰剂给参与者服用时,主要表现出轻度至中度的副作用。副作用包括疲劳、头痛、发冷和肌肉疼痛。该试验受试者也出现发烧,甚至高烧。由于疫苗临床试验为随机、双盲、安慰剂试验,这意味着辉瑞不知道哪些患者接受了疫苗或安慰剂。

该公司已经在其44000个志愿者试验计划中招募了29000多人,以测试与德国合作伙伴BioNTech合作开发的新冠疫苗。据辉瑞公司披露数据称,目前已有超过12000名研究参与者已经接受了第二剂疫苗。

辉瑞公司表示,正在研究中不断审查这种疫苗的安全性和耐受性。辉瑞公司疫苗组的研究负责人凯瑟琳·詹森(Kathrin Jansen)周二审查了新冠疫苗试验的结论性数据,尽管该数据尚未公布,但一些新数据已经在周二进行了审查。来自当前第3期试验的耐受性数据显示,即使在年龄较大的参与者中,也只有中等程度的令人不愉快的副作用,如头痛和肌肉酸痛。

https://www.barrons.com/articles/pfizer-says-its-covid-vaccine-is-just-the-first-in-a-new-wave-of-preventives-51600257601

近期辉瑞公司向投资人更新疫苗管线数据,展示了该公司可能年收入增加200亿美元的产品线。辉瑞疫苗产品在去年416亿美元的销售额中贡献了65亿美元。辉瑞公司将在未来五年内将推出六种新疫苗。辉瑞预计,到2028年,这些新产品和其他新产品将产生其疫苗收入的四分之三,并保护人群达8亿。而且新冠产品甚至并未计入这些预测中。

如果这款新冠疫苗获得批准,辉瑞今年将能够提供1亿剂该型号疫苗,到2021年将再提供13亿剂。美国政府已经订购了4.5亿剂,还有6亿剂的选择权。

在第一波大流行疫苗接种之后,辉瑞公司预计将在2022年推出新冠疫苗的改良版。它还计划针对流感的信使RNA疫苗,其作用将比传统疫苗更广泛、更持久。

此前有报道称,9月6日,辉瑞竞争对手阿斯利康联合牛津大学开发的新冠疫苗试验在英国的受试者中在出现严重副作用,导致在全球范围内暂停试验,在英国监管机构开绿灯后,阿斯利康试验于周一在英国和巴西恢复,但在美国仍被搁置。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2043428, encodeId=2193204342830, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Feb 14 08:30:15 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824354, encodeId=a955182435444, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Jun 07 11:30:15 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028562, encodeId=74f6102856280, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Sep 17 02:30:15 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885931, encodeId=990988593167, content=应该问题不大<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Sep 16 23:40:34 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2021-02-14 ylz8403
  2. [GetPortalCommentsPageByObjectIdResponse(id=2043428, encodeId=2193204342830, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Feb 14 08:30:15 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824354, encodeId=a955182435444, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Jun 07 11:30:15 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028562, encodeId=74f6102856280, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Sep 17 02:30:15 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885931, encodeId=990988593167, content=应该问题不大<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Sep 16 23:40:34 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2043428, encodeId=2193204342830, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Feb 14 08:30:15 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824354, encodeId=a955182435444, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Jun 07 11:30:15 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028562, encodeId=74f6102856280, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Sep 17 02:30:15 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885931, encodeId=990988593167, content=应该问题不大<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Sep 16 23:40:34 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2020-09-17 公卫新人

    新冠肺炎,疫情何时才能消失

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2043428, encodeId=2193204342830, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Feb 14 08:30:15 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824354, encodeId=a955182435444, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Jun 07 11:30:15 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028562, encodeId=74f6102856280, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Sep 17 02:30:15 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885931, encodeId=990988593167, content=应该问题不大<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/3611e9bb629c4e5b81fbd8ce784b06cc/128487eae357460bb98f67d86230c218.jpg, createdBy=ab235268530, createdName=神盾医疗局局长Jack, createdTime=Wed Sep 16 23:40:34 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2020-09-16 神盾医疗局局长Jack

    应该问题不大#新冠肺炎#

    0

相关资讯

阿斯利康/牛津新冠疫苗三期临床将重启

英国药品与健康产品管理局(MHRA,即英国药监局)已建议重启其合作开发的新冠疫苗AZD1222临床三期试验,但声明并未说明具体那一天恢复试验。

Lancet Infect Dis:II价艰难梭菌疫苗III期临床研究失败

类毒素A和B二价艰难梭菌疫苗不能降低高风险人群的艰难梭菌感染风险

因志愿者出现疑似严重不良反应,阿斯利康暂停新冠疫苗三期临床试验

当地时间8日,阿斯利康宣布,该公司将暂停一项正在进行的新冠病毒疫苗试验研究,原因是一名志愿者出现疑似严重的不良反应,这也是首个宣布暂停的已进入三期临床试验的新冠候选疫苗。

JAMA:早产儿依据标准疫苗接种方案后的免疫效果研究

对于早产儿,除b型流感嗜血杆菌疫苗外,按照标准的国家疫苗接种方案可达到较好的免疫预防效果,但与一般人群相比,早产儿的疫苗接种会后的抗体水平一般较低